Introduction {#s1}
============

Paromomycin is an aminoglycosidic antibiotic which was initially used against bacterial infection [@pone.0026660-Davis1]. It is also used against giardiasis, amoebaiasis [@pone.0026660-Gillin1] and cryptosporidiosis [@pone.0026660-Flanigan1]. The mechanism of action of paromomycin has been well studied in *E. coli*. It is known to inhibit protein synthesis by interacting with the ribosomal subunits [@pone.0026660-Davis1]. It has also been shown to inhibit the anti-association activity of initiation factor 3 and promote association of the ribosomal subunits [@pone.0026660-Hirokawa1]. It is known to bind to the major groove in the A-site of 16S rRNA in *E. coli* and induces misreading of mRNA [@pone.0026660-Fourmy1].

The protozoan parasite *Leishmania* is the causative agent of kala-azar and is responsible for a variety of clinical manifestations. Visceral leishmaniasis (VL) is caused by *L. donovani* in the Indian sub-continent. Pentavalent antimonials (SbV) are the first line of drug used in the treatment against all forms of leishmanial infections [@pone.0026660-Khalil1], [@pone.0026660-Sundar1]. Resistance to this drug has become a major barrier in the treatment of VL in many endemic regions particularly in India [@pone.0026660-Lira1]. A parenteral formulation of aminosidine (paromomycin) has been approved for leishmaniasis treatment in India [@pone.0026660-Armijos1]--[@pone.0026660-Sundar2], where it is in phase IV trials (<http://www.oneworldhealth.org/press_releases/release/pr_1227120528>). It has proved to be useful against cutaneous (as both topical and parenteral formulation) and visceral leishmaniasis (as parenteral formulation) [@pone.0026660-elOn1], [@pone.0026660-Scott1].

The mode of action of paromomycin is not clear in case of *Leishmania*. It has been proposed that it might alter membrane fluidity, interact with ribosomes, interfere with the mitochondrial membrane potential and inhibit respiration [@pone.0026660-Maarouf1]. We had earlier elucidated the effect and mechanism of uptake of paromomycin in *Leishmania donovani* [@pone.0026660-Jhingran1]. A line selected for resistance to the drug showed reduced paromomycin accumulation associated with a significant reduction in the initial binding to the cell surface. The drug induced reduction in membrane potential and inhibition of protein synthesis were less pronounced in the resistant strain in comparison to the wild-type [@pone.0026660-Jhingran1]. Recent report indicates differential effects of paromomycin on the translation processes of the *Leishmania* parasite and its mammalian hosts [@pone.0026660-Fernandez1].

Drug resistance is a multifactorial problem due to changes in the expression levels and activity of a wide number of proteins. Quantification of mRNA levels between drug resistant and drug sensitive cell lines unfortunately do not always correlate with protein expression levels due to post-transcriptional changes in protein abundance. Therefore global quantitative proteomics screens are needed to identify the protein targets that are differentially expressed in drug resistant cell lines. Protein profiling has previously been applied to understand the stage- specific gene expression, drug resistance mechanism, identification of virulence factors and characterization of immunodominant antigens [@pone.0026660-Rosenzweig1]--[@pone.0026660-DeaAyuela1]. Earlier reports on comparative protein profiling of the wild type and the antimonial-resistant strain showed that the heat shock protein and kinetoplastid calpain related proteins modulate susceptibility to antimonials [@pone.0026660-Vergnes1]. In another study novel roles were revealed for methionine adenosyl transferase in methotrexate resistance in *Leishmania* [@pone.0026660-Drummelsmith1].

In order to understand the mode of action and possible mechanism of resistance of this antibiotic at the molecular level, we have investigated the protein expression profile of genetically related pair of paromomycin susceptible/-resistant strains. A quantitative proteomic approach based on stable isotope labeling of amino acids in cell culture (SILAC) followed by high resolution mass spectrometry was employed to analyze the differences in the proteome of the wild type and the PRr resistant strain. Paromomycin- resistant promastigotes were generated previously under step-wise exposure to paromomycin and were found to display a three-fold increase in resistance compared to the wild-type [@pone.0026660-Jhingran1]. Drug affinity pull-down assay followed by mass spectrometery revealed a number of proteins in *L. donovani* which might be interacting with paromomycin. Internalization probably then appears to proceed by endocytosis as reported in our earlier studies [@pone.0026660-Jhingran1]. Upregulation of proteins involved in vesicular trafficking in the PRr strain further supports sequestration of drug in the vesicular cytoplasmic compartment. Ultrastructural studies demonstrated increased number of vesicular vacuoles in the PRr strain when compared to the wild-type strain. Up-regulation of proteins involved in the translational machinery especially the ribosomal proteins in the PRr strain indicates that once into the cell PR inhibits protein synthesis by targeting the ribosomal proteins. The identified parasite proteins provide an insight in to the mode of action and underlying mechanism of resistance to paromomycin in *Leishmania.* Furthermore, it allowed us to reinterpret and extend earlier findings, identifying additional processes hitherto only suspected to be involved in its mode of action and underlying mechanism of resistance in *L. donovani.*

Results {#s2}
=======

Identification of Proteins Differentially Expressed in Wild Type (WT) and the Paromomycin Resistant (PRr) Strain {#s2a}
----------------------------------------------------------------------------------------------------------------

We have compared the proteome of the wild type (WT) strain, AG83-S with the PRr strain. Comparative proteomic studies using SILAC technology was employed to reveal proteins that are involved in mediating drug resistance. Briefly, the WT and the PRr strains were cultured in the medium supplemented with normal amino acids \[L-lysine (70 mg/L) and L-arginine (70 mg/L)\] and isotopically labeled ^13^C~6~ L-lysine-HCl and ^13^C~6~ ^15^N~4~ L-arginine-HCl respectively. A schematic diagram illustrating the experimental outline is shown in [Figure 1](#pone-0026660-g001){ref-type="fig"}. Equal amount of protein (100 µg) from the sensitive and the resistant strains were mixed and subjected to the first dimension chromatography and the peptide masses obtained from mass-spectrometry analysis were characterized using the *L. infantum* V3 proteome version 3.0 (<ftp://ftp.sanger.ac.uk/pub/pathogens/L_infantum/>). Supplementary [Table S1](#pone.0026660.s001){ref-type="supplementary-material"} in the supporting information includes all the protein IDs with ≥95% confidence from two individual datasets with their respective ratios and p-values. A total of 226 distinct proteins were identified out of which 197 proteins had a known or predicted function and 29 proteins had no known function (hypothetical proteins). Supplementary [Table S2](#pone.0026660.s002){ref-type="supplementary-material"} includes merged datasets and functional annotation of all the non-redundant proteins identified at ≥95% confidence and ≥2 peptides. According to the functional description, all significantly identified proteins fell into 7 major groups: cell cytoskeleton, metabolic enzymes, chaperones/stress proteins, translation, proteins involved in intracellular survival, RNA and DNA processing, signal transduction and hypothetical proteins. The relative distribution of proteins is shown in [Figure 2](#pone-0026660-g002){ref-type="fig"}. The up- and down- regulated hits are combined in each group.

![Experimental outline of the SILAC experiment.\
Paromomycin resistant cells (PRr) and AG83 wild type (WT) were grown on isotopically heavy and light media respectively. The cells from both the strains were lysed and light and heavy cell lysates were combined. Protein samples were reduced, alkylated and digested with trypsin into peptide samples that were then analyzed by LC-MS/MS. Quantification of SILAC peptide pairs was performed with the SEQUEST algorithm against *L. infantum* protein database ver 3.0 (<ftp://ftp.sanger.ac.uk/pub/pathogens/L_infantum/>). The SEQUEST output files were analyzed and validated by PeptideProphet.](pone.0026660.g001){#pone-0026660-g001}

![Pie diagram showing distribution of *Leishmania* proteins identified by quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels between paromomycin resistant (PRr) and sensitive cells.\
Proteins were grouped according to their cellular functions. The up- and down- regulated hits are combined in each group.](pone.0026660.g002){#pone-0026660-g002}

Among the strictly quantitated proteins, we defined the following thresholds for selecting proteins that had significantly altered expression: 1) proteins identified by the software having ≥95% confidence; 2) the ratio is either ≥1.5 or ≤0.5 and 3) proteins having ≥2 peptides. Applying these filtering criteria, subsets of regulated proteins were identified and then the total number of protein IDs and the number of regulated hits (meeting all three requirements) found in the experiment was determined as detailed in the methods section. The proteins which were ≥1.5 fold were considered to be upregulated whereas the proteins which were ≤0.5 fold were considered to be down regulated. Using these stringent parameters, 29 proteins were found to be up-regulated and 21 proteins were found to be down-regulated and rest of the proteins remained unchanged in the PRr strain in comparison to the wild type ([Table 1](#pone-0026660-t001){ref-type="table"} and [Table 2](#pone-0026660-t002){ref-type="table"}). [Figure 3](#pone-0026660-g003){ref-type="fig"} shows the percentage of up- and down regulated proteins based on their functional classification.

![Bar diagram showing the proteins that were up/downregulated in PR resistant strain.\
The proteins have been grouped according to cellular functions based upon distinct peptides quantitated at ≥95% confidence and having ≥2 peptides.](pone.0026660.g003){#pone-0026660-g003}

10.1371/journal.pone.0026660.t001

###### Proteins upregulated in the paromomycin resistant (PRr) strain.

![](pone.0026660.t001){#pone-0026660-t001-1}

  S. No.                                                               Accession No.                                  Name of the Protein(Up-regulated)                          PRr:WT ratio   P-value    Percent Coverage   Total Number of Peptides
  ------------------------------------------------------------ ------------------------------ --------------------------------------------------------------------------------- -------------- ---------- ------------------ --------------------------
  **Translation**                                                                                                                                                                                                            
  1                                                                    LinJ15_V3.1530                                  Ribosomal protein S6, putative                              1.57±0.4     4.21E-01         34.9                    6
  2                                                             LinJ28_V3.0570LinJ30_V3.3240                           Ribosomal protein s26, putative                             3.47±0.6     2.05E-02         15.2                    2
  3                                                             LinJ28_V3.1050LinJ30_V3.3650                              40S ribosomal protein S14                                 1.65±1      5.39E-01         29.2                    14
  4                                                             LinJ32_V3.0930LinJ35_V3.0600                        60S ribosomal protein L18a, putative                           1.56±0.3     4.07E-01         6.7                     3
  5                                                                    LinJ36_V3.0210                                        Elongation factor 2                                     1.5                         58.8                    5
  **Metabolic Enzymes**                                                                                                                                                                                                      
  **Glycolysis**                                                                                                                                                                                                             
  6                                                                    LinJ14_V3.1240                                              Enolase                                           2.4                         67.8                    9
  7                                                             LinJ21_V3.0300LinJ21_V3.0310                                Hexokinase, putative                                   1.5±1.1      6.52E-01         10.6                    8
  8                                                                    LinJ24_V3.0870                                     Triosephosphate isomerase                                1.51±0.5     5.06E-01         10.8                    9
  9                                                             LinJ30_V3.2990LinJ30_V3.3000                Glyceraldehyde 3-phosphate dehydrogenase, glycosomal                   1.94±0.6     2.68E-01         30.2                   138
  10                                                                   LinJ36_V3.6960                    2,3-bisphosphoglycerate-independent phosphoglycerate mutase               1.57±0.6     4.85E-01         5.6                     2
  **Other Metabolic Enzymes**                                                                                                                                                                                                
  11                                                                   LinJ16_V30560           Orotidine-5-phosphate decarboxylase/orotate phosphoribosyltransferase, putative     1.56±0.5     4.66E-01          12                     21
  12                                                                   LinJ24_V3.0780                                           Malic enzyme                                       1.78±1.5     5.52E-01         4.6                     3
  13                                                                   LinJ27_V3.0300                                  Acyl carrier protein, putative                              1.78±0.2     2.67E-01          12                     4
  14                                                            LinJ30_V3.3560LinJ30_V3.3580                           S-adenosylmethionine synthetase                            1.63±0.07     3.38E-01         2.3                     2
  **Chaperones/Stress Proteins**                                                                                                                                                                                             
  15                                                                   LinJ26_V3.1220                               Heat shock protein 70-related protein                          2.11±0.2     1.50E-01         15.8                    7
  16                                                                   LinJ28_V3.3060                                Heat-shock protein hsp70, putative                             2.5467                       62.5                    10
  17                                                                   LinJ30_V3.2480                Heat shock 70-related protein 1, mitochondrial precursor, putative              2.01                        49.7                    3
  18                                                                   LinJ32_V3.3470                                Chaperonin alpha subunit, putative                            5.75±0.4     6.65E-04         7.9                     5
  19                                                                   LinJ36_V3.7240                                       Chaperonin, putative                                   2.26±0.2     1.16E-01         7.8                     6
  **DNA/RNA Processing**                                                                                                                                                                                                     
  20                                                                   LinJ35_V3.2240                                   RNA-binding protein, putative                              1.5±0.7      5.71E-01         12.4                    8
  21                                                                   LinJ36_V3.3960                              Basic transcription factor 3a, putative                         2.68±0.9     1.07E-01          35                     17
  **Proteins Involved in Intracellular Survival/Processing**                                                                                                                                                                 
  22                                                                   LinJ11_V3.0350                                     14-3-3 protein, putative                                 1.64±0.6     4.41E-01         13.4                    7
  23                                                                   LinJ12_V3.0730                         NADH:flavin oxidoreductase/NADH oxidase, putative                    2.89±2.7     3.13E-01          9                      5
  24                                                                   LinJ19_V3.0150                                     Aminopeptidase, putative                                 1.73±0.2     2.93E-01         11.1                    6
  25                                                                   LinJ20_V3.0820                                  Vesicle-fusing ATPase, putative                             2.8±0.4      5.21E-02         6.1                     3
  26                                                            LinJ24_V3.1560LinJ24_V3.1570                 IgE-dependent histamine-releasing factor, putative                    1.75±0.2     2.88E-01         5.3                     2
  27                                                                   LinJ28_V3.2610                             Vacuolar ATP synthase subunit B, putative                        1.64±1.2     5.75E-01         4.8                     2
  28                                                                   LinJ29_V3.0790                         Lipophosphoglycan biosynthetic protein, putative                     2.01±0.2     1.77E-01         5.6                     3
  29                                                                   LinJ36_V3.3360                                    14-3-3 protein-like protein                               1.56±0.5     4.59E-01         22.9                    10

List of proteins with increased expression levels in the PR resistant strain.

Fold change of protein level measured by SILAC with standard deviation is given as PRr:WT ratio.

p-value determined here were analyzed and validated by PeptideProphet.

10.1371/journal.pone.0026660.t002

###### Proteins downregulated in the paromomycin resistant (PRr) strain.

![](pone.0026660.t002){#pone-0026660-t002-2}

  S. No.                                                               Accession No.                         Name of the Protein(Down-regulated)                  PRr:WT ratio   P-value    Percent coverage   Total Number of Peptides
  ------------------------------------------------------------ ------------------------------ ------------------------------------------------------------------ -------------- ---------- ------------------ --------------------------
  **Translation**                                                                                                                                                                                             
  1                                                                    LinJ11_V3.1160                       Eukaryotic release factor 3, putative                     0.17       1.45E-03         5.3                     3
  2                                                             LinJ18_V3.0630LinJ36_V3.3950                 60S ribosomal protein L10a, putative                   0.24±0.2     1.99E-01          22                     5
  3                                                             LinJ22_V3.1370LinJ22_V3.1410                 40S ribosomal protein L14, putative                    0.23±0.1     8.20E-03         5.2                     4
  4                                                                    LinJ30_V3.0470                         Aspartyl-tRNA synthetase, putative                   0.09±0.01     8.88E-06         3.6                     3
  5                                                                    LinJ35_V3.2040                             60S ribosomal protein L32                         0.27±0.2     1.88E-01         31.6                    5
  Cell cytoskeleton                                                                                                                                                                                           
  6                                                                    LinJ14_V3.1190                               Kinesin K39, putative                           0.3±0.04     2.40E-02         7.3                     2
  **Metabolic Enzymes**                                                                                                                                                                                       
  **Glycolysis**                                                                                                                                                                                              
  7                                                             LinJ20_V3.0110LinJ20_V3.0120                Phosphoglycerate kinase C, glycosomal                   0.1±0.1      6.67E-02         19.1                    14
  **Krebs cycle**                                                                                                                                                                                             
  8                                                                    LinJ35_V3.0850                   NADH-dependent fumarate reductase-like protein             0.47±0.07     1.62E-01         2.3                     3
  9                                                                    LinJ35_V3.1190                    NADH-dependent fumarate reductase, putative               0.24±0.02     5.57E-03         8.5                     6
  **Electron Transport Chain**                                                                                                                                                                                
  10                                                            LinJ05_V3.0500LinJ05_V3.0510                         ATPase alpha subunit                          0.45±0.27     3.12E-01         18.8                    16
  11                                                                   LinJ12_V3.0620                          Cytochrome c oxidase subunit iv                     0.25±0.28     2.61E-01         7.4                     2
  **Other Metabolic Enzymes**                                                                                                                                                                                 
  12                                                                   LinJ31_V3.2320          3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative    0.39±0.03     6.69E-02         8.8                     2
  13                                                                   LinJ35_V3.3390             6-phosphogluconate dehydrogenase, decarboxylating putative       0.36±0.03     4.79E-02         8.6                     3
  **Chaperones/Stress Proteins**                                                                                                                                                                              
  14                                                                   LinJ21_V3.1330                    t-complex protein 1, delta subunit, putative              0.47±0.03     1.40E-01          12                     4
  15                                                                   LinJ35_V3.3900                     t-complex protein 1, eta subunit, putative                0.42±0.1     1.09E-01         15.6                    6
  **DNA/RNA Processing**                                                                                                                                                                                      
  16                                                                   LinJ15_V3.1500                Proliferative cell nuclear antigen (PCNA), putative            0.27±0.1     2.87E-02         11.6                    3
  17                                                                   LinJ19_V3.0090                               Fibrillarin, putative                           0.45±0.1     1.69E-01         12.2                    2
  18                                                                   LinJ32_V3.0410                        ATP-dependent RNA helicase, putative                   0.27±0.2     1.58E-01         11.9                    6
  **Proteins Involved in Intracellular Survival/Processing**                                                                                                                                                  
  19                                                                   LinJ35_V3.0070                                Prohibitin, putative                           0.4±0.03     7.79E-02         7.9                     2
  **Hypothetical Proteins**                                                                                                                                                                                   
  20                                                                   LinJ10_V3.0910                          Hypothetical protein, conserved                      0.47±0.1     1.48E-01         12.8                    2
  21                                                                   LinJ35_V3.0140                          Hypothetical protein, conserved                      0.22±0.2     1.61E-01         21.8                    3

List of proteins with decreased expression levels in the PR resistant strain.

Fold change of protein level measured by SILAC with standard deviation is given as PRr:WT ratio.

p-value reported here were analyzed and validated by PeptideProphet.

Increased Glycolysis and Energy producing Metabolic Pathways in the Paromomycin Resistant strain (PRr) {#s2b}
------------------------------------------------------------------------------------------------------

*Leishmania* mainly uses glycolytic and pentose phosphate pathway enzymes for energy generation. Several enriched biological pathways from the subset of proteins identified with increased expression in the paromomycin resistant *L. donovani* are related to glycolysis. The enzymes of the glycolytic pathway were found to be significantly upregulated in the PRr strain except for the enzyme phoshoglycerate kinase which was found to be downregulated (∼10 fold) in the PR resistant strain. Other proteins, such as NADH dependent fumarate reductase putative and NADH dependent fumarate reductase like protein were also found to be downregulated (∼4 and ∼2 fold respectively) in the paromomycin resistant cells. This enzyme is involved in the conversion of fumarate to succinate and enables the organism to switch to anaerobic respiration. The protein 6-phosphogluconate dehydrogenase, the first committed enzyme of the pentose phosphate pathway was also found to be down regulated (∼2.7 fold) in the paromomycin resistant parasites. This indicates that the PRr strain heavily relies on glycolysis for its energy requirements. Increased glycolytic activity under normal aerobic conditions is probably associated with mitochondrial dysfunction. A high glycolysis rate also helps reduce oxidative stress because the product of anaerobic glycolysis, pyruvate, is a scavenger of hyperoxide.

Additional enriched metabolic pathways with enzymes displaying altered expression levels include the TCA cycle and lipid metabolism. Proteins involved in oxidative phosphorylation, ATPase alpha subunit and cytochrome c oxidase subunit IV were found to be downregulated in the PRr strain. Acyl carrier protein, which is a part of Type II fatty acid synthesis pathway, was found to be upregulated (∼1.8-fold) in the PRr strain. This pathway is used for lipoic acid biosynthesis which is an essential co-factor for the mitochondrial enzymes pyruvate dehydrogenases and 2-keto glutarate dehydrogenase present in the TCA cycle [@pone.0026660-vanWeelden1]. Another enzyme, S-adenosyl methionine synthetase was found to be ∼1.6 upregulated in the PRr strain. S-adenosyl methionine dependent RNA methylase, which methylates 16S rRNA in *E. coli* has been associated with resistance to kasugamycin, an inhibitor of protein synthesis [@pone.0026660-VilaSanjurjo1].

Modulation of Proteins Involved in Intracellular Survival, Processing and Virulence {#s2c}
-----------------------------------------------------------------------------------

The vesicular sequestration of drugs is a well known mechanism of drug resistance in some mammalian cell lines which results in lower cytoplasmic drug levels by sequestration of drugs in to a vesicular cytoplasmic compartment [@pone.0026660-Kramer1]--[@pone.0026660-Sognier1]. Drug resistance by sequestration in the vesicles has also been proposed for the antimony resistant *Leishmania* parasites. In *Leishmania*, trivalent antimony conjugates to trypanothione and is sequestered inside a vacuole by ABC (ATP binding cassette) transporter, P glycoprotein A (PGPA) [@pone.0026660-Legare1]. We observed upregulation of both vesicle-fusing ATPase (∼2.8 fold) and vacuolar ATP synthase subunit B (∼1.6 fold) in the PRr strain.

Transmission electron microscopy was employed in order to document the differences between the wild type and the PRr strain. The ultra-structural analysis of the paromomycin resistant strain revealed a greater number of vesicular vacuoles when compared to the sensitive wild type strain ([Figure 4A and B](#pone-0026660-g004){ref-type="fig"}). It is possible that vesicular sequestration of paromomycin into vacuoles by these resistant parasites might be involved in conferring the resistance phenotype.

![Transmission Electron Microscopic (TEM) images of the A. Wild Type (WT) promastigotes and B. Paromomycin resistant promastigotes.\
WT promastigotes were harvested and fixed as mentioned in Materials and methods and subjected to TEM analysis. PRr strain displayed numerous vacuoles compared to the wild type strain. Images are representative of 2 independent experiments. FP: Flagellar Pocket; V: Vacuole; N: Nucleus; K: Kinetoplast.](pone.0026660.g004){#pone-0026660-g004}

We also observed increased expression of proteins that are involved in intracellular survival and virulence including lipophosphoglycan biosynthetic protein (LPG) putative, aminopeptidase IgE-dependent histamine releasing factor and NADH oxidase putative. Another protein, prohibitin, showed decreased protein expression levels (∼2.5 fold) in the PRr resistant strain. Prohibitin has been reported to play an important role in the events leading to *Leishmania-*host interaction [@pone.0026660-Jain1]. Its homolog has been studied in *Trypanosoma brucei* and has been reported to be upregulated upon induction of apoptosis [@pone.0026660-Welburn1]. Down regulation of prohibitin in the present study possibly indicates that the PR resistant cells are able to survive by suppressing the expression of pro-apoptotic proteins. Two proteins, annotated as "14-3-3 protein like protein" and "14-3-3 protein putative" were found to be upregulated in the PRr strain. These proteins are capable of binding to numerous phosphorylated proteins including transcription factors, biosynthetic enzymes, cytoskeletal proteins, signaling molecules and display important anti-apoptotic characteristics [@pone.0026660-Dougherty1].

Chaperones and Stress Proteins {#s2d}
------------------------------

A number of chaperones and stress proteins showed increased expression levels in the PRr strain. Analysis of the data revealed upregulation in the levels in the PRr strain; namely three HSPs (\>2 fold) and two chaperonins (\>2 fold). All the three HSPs belong to the HSP70 family. Heat shock proteins have been shown to confer resistance against drugs [@pone.0026660-Brochu1].

Proteins involved in Translation Machinery {#s2e}
------------------------------------------

Paromomycin is known to bind to the small subunit of ribosomes and inhibit protein synthesis [@pone.0026660-Davis1]. Our data analysis revealed that three out of four significantly upregulated proteins are components of small ribosomal subunit. A total of 56 proteins involved in translation including ribosomal subunit proteins and translation factors were identified by SILAC. Upregulation of ribosomal proteins rpS26 (∼3.5 fold) and rpS6 (∼1.57 fold) was detected in the paromomycin resistant strain. These two proteins have also been found to be involved in self-translation regulation in humans. Ribosomal protein, rpS26 has been shown to be important for the normal growth of *S. cerevisiae* [@pone.0026660-Wu1]. Ribosomal protein, rpL18a putative has been implicated in cell growth regulation and was seen to be upregulated (∼1.5 fold). Translational factor, EF3 was found to be downregulated in the paromomycin resistant strain (∼5.88 fold).

Proteins Involved in DNA/RNA Processing {#s2f}
---------------------------------------

A few proteins involved in transcription were also identified including some of the histones which are important for DNA replication and nucleosome assembly. Basic transcription factor 3a (BTF3a) putative was found to be ∼3 fold upregulated. It has been observed that down-regulation of BTF3a is involved in inhibition of transcription and proteins synthesis in the apoptotic K562 cells [@pone.0026660-Li1]. It also acts as a transcriptional regulator and is associated with apoptosis and/or cell cycle arrest [@pone.0026660-Kusumawidjaja1], [@pone.0026660-Brockstedt1]. Two of the nucleic acid associated proteins involved in RNA processing were found to be significantly down regulated in case of the PR resistant strain. Fibrillarin, a key small nucleolar protein in eukaryotes which plays an important role in ribosomal biogenesis was found to be ∼2.2 fold downregulated in the PR resistant strain [@pone.0026660-Amin1]. Fibrillarin (NOP1) is highly conserved throughout evolution from unicellular organisms such as yeast and trypanosomes to humans [@pone.0026660-Jansen1]. It is involved in rRNA processing and modification in *Trypanosoma brucei* [@pone.0026660-Barth1]. A NOP1 knockout is lethal in *S. cerevisiae* and mutants of this gene exhibit defects in pre-rRNA processing, modification and ribosome assembly [@pone.0026660-Tollervey1].

Drug Affinity Pull Down-Assay of the Paromomycin Interacting Proteins {#s2g}
---------------------------------------------------------------------

The combination of drug affinity pull-down assays with in situ digestion and LC-MS/MS analysis is a useful tool in obtaining complex information about a primary drug target as well as its protein interactors. Pull down-assay using the PR linked resin followed by LC-MS/MS analysis revealed a number of proteins upon LC-MS/MS analysis which might be interacting with PR inside the cell. The basic scheme of the experiment is shown in [Figure 5](#pone-0026660-g005){ref-type="fig"}.The data obtained for PR linked and unlinked resins were compared to obtain the proteins that bound exclusively to the PR linked resin. The identified proteins that interacted with PR are listed in [Table 3](#pone-0026660-t003){ref-type="table"}. Of particular interest were the paraflagellar rod proteins 1D and 2C, found only in the flagellum of the parasites [@pone.0026660-de1]. Another protein, prohibitin was also found to interact with PR. Prohibitin in *Leishmania* is reported to be concentrated at the surface of the flagellar and the aflagellar pole [@pone.0026660-Jain1]. The flagellar pocket membrane is the only part of the cell surface that supports endocytosis and exocytosis [@pone.0026660-Overath1]. The present data further supports the role of such a process in drug uptake. Another protein, P-type H^+^ ATPase putative was also found to be interacting with PR. This protein is reported to be localized in the intracellular compartments and is involved in the acidification and forms a part of endocytic pathway in *Trypanosoma cruzi* [@pone.0026660-Vieira1]. It is possible that the PR interacts with this protein after it is endocytosed or sequestered in the vesicles by the parasite.

![Overview of the affinity pull-down assay using PR-linked resin.\
Paromomycin was bound to AminoLink Plus coupling resin. The PR-linked resin (experimental) and unlinked resin (used as negative control) were incubated with AG83 whole cell lysate. The beads were then washed and the resin was loaded onto 10% SDS-PAGE gel. The gel was stained with sypro ruby and the fragments were excised and digested with trypsin. The protein samples were analyzed by LC-MS/MS and the results compared to determine the proteins that interacted with PR selectively.](pone.0026660.g005){#pone-0026660-g005}

10.1371/journal.pone.0026660.t003

###### Drug affinity pull-down assays with in situ digestion and LC-MS/MS analysis identified proteins from wild type *L. donovani* promastigotes that bind to paromomycin.

![](pone.0026660.t003){#pone-0026660-t003-3}

  S. No.                    Accession No.                             Name of Protein            Number of Peptides   Probability   Percent coverage
  -------- ------------------------------------------------ ----------------------------------- -------------------- ------------- ------------------
  1\.                LinJ16_V31510, LinJ16_V31520              Paraflagellar rod protein 2C              2                 1              4.3
  2\.       LinJ18_V3.1490, LinJ18_V3.1500, LinJ18_V3.1510      P-type H+-ATPase, putative               3               0.99             5.8
  3\.               LinJ29_V3.1880,LinJ29_V3.1890              Paraflagellar rod protein 1D              5                 1              9.3
  4\.                       LinJ31_V3.2680                   RNA Polymerase II largest subunit           1               0.99             1.1
  5\.                       LinJ35_V3.0070                              Prohibitin                       1               0.95             4.8

The protein coverage is based on the non-redundant peptides identified by PeptideProphet.

The results are representative of two independent experiments.

Discussion {#s3}
==========

The control of leishmaniasis relies mainly on a few chemotherapeutic agents and emerging resistance towards these agents is one of the major clinical problems today. Paromomycin, an aminoglycoside antibiotic, is one of the drugs currently used in the chemotherapy of cutaneous and visceral leishmaniasis. Paromomycin inhibits protein synthesis by interacting with ribosomal RNA subunits [@pone.0026660-Davis1]. However, its mode of action is not well understood in *Leishmania spp.* Reports suggest that paromomycin might act by interacting with the ribosomes or disrupting the mitochondrial membrane potential [@pone.0026660-Maarouf1], [@pone.0026660-Jhingran1]. In order to understand the mode of action of this antibiotic at the molecular level, we employed a quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels between paromomycin resistant (PRr) and sensitive cells.

We had earlier elucidated the effect and mechanism of uptake of paromomycin in *Leishmania donovani* [@pone.0026660-Jhingran1]. Our earlier work suggests binding of the cationic paromomycin to the negatively charged leishmanial glycocalyx. In bacteria, aminoglycosides are reported to associate with lipopolysaccharide (LPS) and other anionic components of the bacterial cell surface [@pone.0026660-Magnet1]. Lipophosphoglycan (LPG), a highly negatively charged molecule is a major component of the cell surface of promastigotes of *Leishmania* [@pone.0026660-GuhaNiyogi1], [@pone.0026660-Ilgoutz1]. Several glycosylphosphatidylinositols have been reported to accumulate in the endosomes [@pone.0026660-Zheng1], [@pone.0026660-Glaser1]. We had earlier proposed that paromomycin associates with LPG at the leishmanial surface and also suggested other components may also be involved in binding. Our hypothesis was that after binding to the surface, internalization appears to proceed by endocytosis since a number of typical inhibitors of endocytosis reduced the rate of uptake of the drug [@pone.0026660-Jhingran1]. Once inside the cell it is possible that the drug enters the mitochondrion. The uptake of this cationic agent in the mitochondria is dependent on the high membrane potential [@pone.0026660-Jhingran1].

The present study was aimed to investigate the global proteome differences between the wild type AG83 strain and a paromomycin resistant (PRr) strain of *L. donovani*. [Table 4](#pone-0026660-t004){ref-type="table"} gives a brief summary of the classes of proteins that were altered in the PR resistant strain. The identified parasite proteins further support our earlier understanding of the mode of action and underlying mechanism of resistance to paromomycin in *Leishmania*. Proteome screens have been shown to be useful for identifying novel resistance mechanisms. The data revealed changes in the level of proteins involved in metabolic processes like glycolysis and those involved in other fundamental processes like translation, transcription, signal transduction, chaperones/stress, intracellular survival and pro-apoptosis.

10.1371/journal.pone.0026660.t004

###### Modulation in expression of proteins in paromomycin -susceptible (AG83 WT) and -resistant (PRr) *Leishmania donovani.*

![](pone.0026660.t004){#pone-0026660-t004-4}

  Cellular Function                                                                                      Proteins modulated in the Paromomycin resistant strain
  -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intracellular Survival, Processing and Virulence    14-3-3 protein, LPG biosynthetic protein and IgE dependent histamine release factor were found to be upregulated. Prohibitin was found to be downregulated.
  Vesicle trafficking                                     Proteins involved in vesicle trafficking, fusion and endocytosis like vesicle fusing ATPase and vacuolar ATP synthase were found to be upregulated.
  Translation                                               Ribosomal proteins were found to be upregulated in the PR resistant strain. This may be because PR is known to inhibit translation in *E. coli*
  Chaperones/stress proteins                          Heat shock proteins and chaperonins were found to be upregulated. HSPs protect cell from toxic external stimuli and have been implicated in drug resistance.
  Metabolism                                                                                          Proteins involved in glycolysis were seen to be upregulated

Several of the proteins involved in the translational machinery, especially the ribosomal proteins, were found to be upregulated in the resistant strain ([Table 1](#pone-0026660-t001){ref-type="table"}). In *Leishmania*, paromomycin has been implicated in targeting ribosomes directly and differential effects of paromomycin on the translation processes of the *Leishmania* parasite and its mammalian hosts has also been reported [@pone.0026660-Maarouf2]. In light of this, our data on the up-regulation of the ribosomal proteins could be explained as one of the mechanisms utilized by the resistant parasites as a defence against paromomycin. Furthermore, our previous report also shows an overall less percent inhibition of protein synthesis by paromomycin in the PRr strain as compared to the WT [@pone.0026660-Jhingran1].

Of the upregulated proteins in the PRr strain, LPG putative deserves special attention as it has been identified as a virulence factor in *Leishmania* [@pone.0026660-Descoteaux1]. Lipophosphoglycan biosynthetic protein, putative or *LPG3* is an ortholog of eukaryotic glucose regulated protein 94 (GRP 94). Its null mutants in *Leishmania* are viable but show severe defects in phosphoglycosylation. Its role has been found to be restricted to the synthesis of glycoconjugates implicated in parasite virulence, including LPG and other PG-bearing molecules and GPI-anchored proteins [@pone.0026660-Descoteaux1].

LPG biosynthetic protein, vesicle fusing ATPase and vacuolar ATPase were upregulated in the PR resistant strain. The ultra-structural studies of the paromomycin resistant strain revealed the presence of increased number of vesicular vacuoles in comparison to the sensitive wild type strain ([Figure 4](#pone-0026660-g004){ref-type="fig"}).

Affinity pull-down assay using PR linked resin identified proteins that interact with PR. Paraflagellar rod proteins and prohibitin were found to interact with paromomycin. Prohibitin in *Leishmania* is also reported to be concentrated at the surface of the flagellar and the aflagellar pole [@pone.0026660-Jain1]. It is well known that the flagellar pocket facilitates internalization of the molecules. Hence binding of PR to the paraflagellar rod proteins and prohibitin is of significance in the present study.

In summary, it is clear that the molecular mechanisms contributing to paromomycin resistance comprise a complex multifactorial network. In view of our earlier and present studies we propose the following mode of action for PR in *L. donovani* ([Figure 6](#pone-0026660-g006){ref-type="fig"}). It is proposed that the drug binds to the paraflagellar rod proteins and prohibitin and then internalization appears to proceed by endocytosis since a number of typical inhibitors of endocytosis reduced the rate of uptake of the drug [@pone.0026660-Jhingran1]. Another protein, P-type H^+^ ATPase putative was also found to interact with PR. This protein is localized in the intracellular compartments and is reported to be involved in acidification and forms a part of endocytic pathway in *Trypanosoma cruzi* [@pone.0026660-Vieira1]. It is possible that PR interacts with this protein after it is endocytosed or sequestered in the vesicles by the parasite. The vesicular sequestration of paromomycin into the internal vesicles by the parasite using fluorescent derivative of the aminoglycoside antibiotic, paromomycin would be required to show that the drug accumulates in the vesicles. It is possible that vesicular sequestration of paromomycin in to the vacuoles by these resistant parasites might be involved in conferring the resistance phenotype. Once inside the cell PR inhibits protein synthesis by targeting several of the proteins involved in the translational machinery, in particular the ribosomal proteins. Overall, this study characterized the mode of action and underlying mechanism of resistance to paromomycin in *Leishmania donovan*i. However, further investigation of vesicle-mediated mechanism of paromomycin resistance is presently going on in the laboratory to conclusively show drug sequestration into the internal vesicles of the resistant parasites.

![Proposed model for mechanism of paromomycin resistance in *L. donovani*.\
(I) The drug paromomycin (red circles) interacts with paraflagellar rod proteins (blue circles) and prefoldin (yellow circles) and is then taken up by the *Leishmania* promastigotes by endocytosis. PR is then sequestered in to the vacuoles. The pump, vacuolar ATPase is found to be upregulated and the number of vacuoles is increased in the resistant parasites. (II) The chaperone proteins are found to be upregulated in the resistant cells as a result of the stress caused by paromomycin and are also involved in increased protein turnover. (III) A number of ribosomal protein subunits were found to be regulated, increasing the total protein synthesis. (IV) The glycolytic pathway was found to be upregulated. Proteins marked in red represent the upregulated proteins and the ones marked in green represent the down- regulated proteins in the case of paromomycin resistant strain. Enzymes indicated: (**1**) Hexokinase, (**2**) Phosphoglucose isomerase, (**3**) Phosphofructokinase, (**4**) Aldolase (**5**) Triose phosphate isomerase, (**6**) Glyceraldehyde 3-phosphate dehydrogenase, (**7**) Phosphoglycerate kinase (**8**) 2,3-bisphosphoglycerate independent phosphoglycerate mutase, (**9**) Enolase, (**10**) Pyruvate kinase, (**11**) Malic enzyme (**12**) glucose 6-phosphate dehydrogenase.](pone.0026660.g006){#pone-0026660-g006}

Materials and Methods {#s4}
=====================

Chemicals {#s4a}
---------

The medium M199 deficient in L-lysine and L-arginine was custom synthesized from SAFC biosciences (MO, USA). The labeled amino acids, ^13^C~6~ L-lysine-HCl and ^13^C~6~ ^15^N~4~ L-arginine-HCl were obtained from Pierce Biotech (Illinois, USA). Dialyzed fetal bovine serum was purchased from Invitrogen (CA, USA). Mass spec (MS) grade trypsin was purchased from Promega (WI, USA). AminoLink coupling resin was purchased from Pierce Biotech (IL, USA). All the solvents used for preparation and running of samples were of MS grade and were available commercially.

Parasite and Culture Conditions {#s4b}
-------------------------------

Promastigotes of *Leishmania donovani* clones, AG83 (MHOM/IN/80/AG83) wild-type (WT) and a paromomycin resistant strain (PRr) were used in the present study. PRr strain used in this study was raised in the laboratory as reported [@pone.0026660-Jhingran1]. PRr strain had an IC~50~ of 145 µM and was three-fold resistant to paromomycin compared to the wild-type [@pone.0026660-Jhingran1]. Promastigotes were routinely cultured at 22°C in modified M-199 medium (Sigma, St. Louis. MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco/BRL, Life Technologies Scotland, UK) and 0.13 mg/mL penicillin and streptomycin.

SILAC Labeling of Cells {#s4c}
-----------------------

For SILAC analysis, promastigotes were grown in custom synthesized media, M199 depleted of L-lysine and L-arginine (Sigma, USA) supplemented with 10% dialyzed fetal bovine serum (Invitrogen, Carlsbad, CA, USA), antibiotics and one of the two SILAC media formulations at 22°C \[normal isotopic abundance L-lysine (70 mg/L) and L-arginine (70 mg/L)\] for the wild type and ^13^C~6~ L-lysine-HCl and ^13^C~6~ ^15^N~4~ L-arginine-HCl (Pierce Biotechnology) for the PRr parasites\] ([Fig. 1](#pone-0026660-g001){ref-type="fig"}). A regular sub-culturing in this medium was done for at least six cell divisions in order to achieve 100% labeling of the cellular proteins before analysis.

Preparation of Protein Samples {#s4d}
------------------------------

The cells were harvested, washed with 1X PBS and lysed. The protein was quantitated by Bradford\'s method [@pone.0026660-Bradford1] and equal amount of protein (100 µg) from both the cell lysates was mixed and separated by 10% SDS-PAGE and stained with Sypro Ruby stain (Bio-Rad). The entire gel lane was cut into 10 sections for in-gel digestion. Each section was further cut into small pieces of approximately 1 mm each. The gel pieces were dehydrated in the presence of 50% acetonitrile and then rehydrated with 50 mM ammonium bicarbonate. Digestion of the samples was carried out using sequencing grade modified trypsin (Promega) (12.5 ng/µl) in 50 mM ammonium bicarbonate at 37°C overnight. The tubes were then centrifuged and supernatant collected. The peptides were extracted from the gel using 20 mM ammonium bicarbonate, followed by extraction with 5% formic acid in 50% acetonitrile. The samples were dried in speedvac and stored at −80°C till further analysis.

Liquid Chromatography--Mass Spectrometry (LC-MS/MS), Data Base Analysis and Relative Quantification {#s4e}
---------------------------------------------------------------------------------------------------

LC-MS/MS was performed using LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific). The LC system consisted of a fused-silica nanospray needle packed in-house with C18 reverse-phase material. The peptide samples were loaded onto the reversed phase column using a two-mobile-phase solvent system consisting of 0.4% acetic acid in water (A) and 0.4% acetic acid in acetonitrile (B) at a flow rate of 200 µl/min. The mass spectrometer operated in a data-dependent MS/MS mode over the *m/z* range of 400--2000. For each cycle, the five most abundant ions from each MS scan were selected for MS/MS analysis using 45% normalized collision energy. Dynamic exclusion was used to exclude ions that had been detected twice in a 30 sec window for 3 min. Raw MS/MS data were submitted to Bioworks 3.3 (ThermoElectron, San Jose, CA, USA) and searched using the SEQUEST algorithm against *L. infantum* protein database ver 3.0 (<ftp://ftp.sanger.ac.uk/pub/pathogens/L_infantum/>). The SEQUEST output files were analyzed and validated by PeptideProphet. Proteins and peptides with a probability score of ≥0.9 were accepted. The quantification was based on two independent SILAC and LC-MS/MS experiments.

Transmission Electron Microscopy {#s4f}
--------------------------------

Cells were fixed in a solution of 2% paraformaldehyde and 2.5 mM CaCl~2~ in 0.1 M sodium cacodylate buffer pH 7.2, post-fixed in 1% osmium tetroxide and 0.8% potassium ferricyanide in the same buffer, dehydrated in an acetone series and embedded in Polybed resin. Thin sections were stained with uranyl acetate and lead citrate and observed under a FEI Morgagni™ transmission electron microscope. Images are representative of 2 independent experiments.

Affinity Pull-Down of the Paromomycin Interacting Proteins {#s4g}
----------------------------------------------------------

Paromomycin (PR) was linked to AminoLink plus coupling resin (Pierce Biotechnology) according to the manufacturer\'s protocol (the resin contains aldehyde groups that react with primary amines present in paromomycin to form Schiff\'s base bonds). The unbound paromomycin was removed by centrifuging the resin at 2000 rpm and then washing with 1 X phosphate buffered saline (PBS), pH 7.2. The binding efficiency of the beads with PR was found to be 66%. Wild-type AG83 cells (1×10^8^) were harvested and lysed with lysis buffer (10 mM Tris.Cl pH 7.2, 10 mM MgCl~2~, 150 mM KCl, 0.1% Triton-X 100, 1% BSA and protease inhibitor cocktail). The lysate was incubated with paromomycin-linked agarose beads for 2 h at 4°C with continuous mixing. The suspension was then centrifuged at 2000 rpm for 10 min at 4°C and the beads were transferred to a fresh tube. The beads were washed four times with a wash buffer (10 mM Tris.Cl pH 7.2, 10 mM MgCl~2~, 150 mM KCl and 0.1% Triton-X 100) and finally resuspended in 1X SDS PAGE dye and loaded onto 10% SDS-PAGE gel. The gel was stained with Sypro Ruby stain and the bands were visualized under UV and desired bands were cut and subjected to the LC-MS/MS analysis in a 4000 Q TRAP LC-MS/MS system (Applied Bisosytems MDS SCIEX) for peptide ionization and detection. The SEQUEST output files were analyzed and validated by PeptideProphet. Proteins and peptides with a probability score of ≥0.9 were accepted. Beads not linked with paromomycin were used as negative control. The results are representative of two independent experiments.

Supporting Information {#s5}
======================

###### 

**List of proteins identified in Set A and Set B at ≥95% confidence.**

(XLS)

###### 

Click here for additional data file.

###### 

**Proteins identified using SILAC and categorized on the basis of function quantitated at \>95% confidence and having ≥2 peptides.**

(XLS)

###### 

Click here for additional data file.
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